Why the study?
Does endovascular renal denervation provide clinical benefits beyond blood pressure lowering in patients with chronic kidney disease?
Does endovascular renal denervation provide clinical benefits beyond blood pressure lowering in patients with chronic kidney disease?
Endovascular renal denervation may offer pleiotropic benefits beyond blood pressure reduction by modulating sympathetic hyperactivity, which is particularly relevant for chronic kidney disease progression.
Should not yet change CKD practice; leaves open pleiotropic benefits of renal denervation pending randomized trials.
Endovascular renal denervation (sympathectomy) is a novel procedure developed for the treatment of resistant hypertension. Evidence suggests that it reduces both afferent and efferent sympathetic nerve activity, which may offer clinical benefit over and above any blood pressure-lowering effect. Studies have shown objective improvements in left ventricular mass, ventricular function, central arterial stiffness, central haemodynamics, baroreflex sensitivity and arrhythmia frequency. Benefits have also been seen in insulin resistance, microalbuminuria and glomerular filtration rate. In chronic kidney disease, elevated sympathetic activity has been causally linked to disease progression and cardiovascular sequelae. Effecting a marked reduction in sympathetic hyperactivity may herald a significant step in the management of this and other conditions. In this in-depth review, the pathophysiology and clinical significance of the sympatholytic effects of endovascular renal denervation are discussed.
No takes yet. Share an insight, caveat, or question.
Hoye et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: